ORTHO-EST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORTHO-EST (ORTHO-EST).
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.
| Metabolism | Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates. |
| Excretion | Renal elimination (90-95%) as glucuronide and sulfate conjugates; fecal (5-10%) via biliary excretion. |
| Half-life | 12-18 hours (terminal elimination half-life); clinical context: dosed once daily, steady-state achieved in 5-7 days. |
| Protein binding | 50-80% bound to albumin and sex hormone-binding globulin (SHBG); binding to SHBG is approx. 30-50%. |
| Volume of Distribution | 1-2 L/kg; clinical meaning: extensive distribution into tissues, including fat and reproductive organs. |
| Bioavailability | Oral: 40-60% due to first-pass metabolism; transdermal: approximately 10-20% systemic availability (not primary route). |
| Onset of Action | Oral: 2-4 hours for symptom relief (e.g., vasomotor symptoms). |
| Duration of Action | 24 hours after a single oral dose; clinical notes: daily dosing required for continuous effect. |
1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 mL/min): use with caution due to potential accumulation of conjugated estrogens. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: contraindicated due to impaired estrogen metabolism. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | Initiate at lowest effective dose (0.625 mg orally once daily) and titrate cautiously due to increased risk of thromboembolic events and endometrial cancer. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-EST (ORTHO-EST).
| Breastfeeding | Estradiol is excreted in human breast milk at low concentrations. The M/P ratio is approximately 0.2–0.3. It may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the immediate postpartum period when milk supply is being established. Alternate methods of contraception should be considered. |
| Teratogenic Risk | ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., cardiovascular, limb defects, VACTERL association) based on epidemiological data. Second and third trimester exposure may cause fetal harm including urogenital tract abnormalities and potential carcinogenic effects. Estrogens are not recommended for use in pregnancy. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. They should not be used during pregnancy. There is an increased risk of cardiovascular events (e.g., stroke, myocardial infarction) and breast cancer with estrogen-alone therapy.
| Serious Effects |
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in select cases), known or suspected estrogen-dependent neoplasia, active or history of venous thromboembolism, active or history of arterial thromboembolism, hypersensitivity to estrogens, hepatic impairment or disease, protein C, protein S, or antithrombin deficiency.
| Precautions | Cardiovascular disorders (thrombophlebitis, thromboembolism), malignancy (breast, endometrial), gallbladder disease, hypercalcemia, fluid retention, hepatic impairment, hypothyroidism, and hereditary angioedema. |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required because use is contraindicated in pregnancy. For accidental exposure, fetal ultrasound and echocardiography may be considered to assess for congenital anomalies. maternal blood pressure and liver function should be monitored if exposure occurs. |
| Fertility Effects | Estradiol can affect fertility by its mechanism as a contraceptive. It inhibits ovulation when used in combination with a progestin, but as a monotherapy, it may disrupt menstrual cycles and suppress ovulation. Return to fertility is expected upon discontinuation. However, prolonged use may delay conception. No permanent effects on fertility have been documented. |